Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Opposing effects of immun… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?

Artikel i vetenskaplig tidskrift
Författare Örjan Strannegård
Fredrik Bergh Thorén
Publicerad i Oncoimmunology
Volym 5
Nummer/häfte 3
Sidor e1091147
ISSN 2162-402X
Publiceringsår 2016
Publicerad vid Sahlgrenska Cancer Center
Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor e1091147
Språk en
Länkar dx.doi.org/10.1080/2162402x.2015.10...
Ämnesord Immunotherapy, Type I interferon, immunoediting, treatment outcome, antigen expression, prostate-cancer, clinical-trials, phase-iii, survival, vaccine, Oncology
Ämneskategorier Klinisk medicin

Sammanfattning

With checkpoint inhibitors, patients with advanced melanoma display durable responses suggesting cure of disease. However, the immune system has dual roles in cancer; while the immune system may eradicate a tumor, a subtotal elimination may selectively destroy immunogenic cells driving the proliferation of non-immunogenic tumors. Here, we performed a retrospective analysis of results obtained in a controlled trial of patients with melanoma treated with adjuvant, multisubtype interferon-. The survival curves displayed a late divergence for treated patients and controls resulting in substantially higher estimates of overall (OS) and relapse-free survival (RFS) rates among treated patients after 9 y of follow up. Interestingly, succumbing patients in the treatment group displayed reduced time between relapse and death, suggesting therapy-induced acceleration of disease progression. These findings suggest that effective immunotherapy that induces durable, curative responses in some patients, may potentially accelerate disease progression in others, highlighting the importance of developing advanced strategies to identify patients who are likely to benefit from immunotherapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?